Growth factors, medicine and synthetic peptides
At the forefront of Matsumoto's research is the potential targeting of HGF and its receptor MET in regeneration and cancer, leading to drug discovery. He started bioventure to facilitate his research to clinical application. Clinical trials of HGF protein for treatment of amyotrophic lateral sclerosis/ALS and spinal cord injury are ongoing. He recently discovered artificial HGF composed of synthetic peptides. The artificial HGF can be the next generation biological drug by chemical synthesis. Peptides targeting HGF-MET pathway will be invaluable in the drug discovery for diagnosis and therapeutics of cancer.
Keywords: ATOMIC FORCE MICROSCOPY (AFM); BIOLOGICAL PATHWAYS; CANCER; DRUG DISCOVERY; DRUG RESISTANCE; HEPATOCYTE GROWTH FACTOR (HGF); HGF-MET IN CANCER; MACROCYCLE PEPTIDE; METASTASIS; PROTEIN; RAPID SYSTEM; TISSUE REGENERATION; TUBULOGENESIS; TUMOUR GROWTH; TUMOUR PROGRESSION
Document Type: Research Article
Publication date: June 1, 2018
Impact is a series of high-quality, open access and free to access science reports designed to enable the dissemination of research impact to key stakeholders. Communicating the impact and relevance of research projects across a large number of subjects in a content format that is easily accessible by an academic and stakeholder audience. The publication features content from the world's leading research councils, policy groups, universities and research projects. Impact is published under a CC-BY Creative Commons licence.
- Subscribe to this Title
- Terms & Conditions
- Disseminating research in Impact
- Information about Impact
- Ingenta Connect is not responsible for the content or availability of external websites